PetVivo Acquires PiezoBioMembrane to Enhance IP Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: Newsfilter
- Acquisition Overview: PetVivo Holdings has announced a merger agreement to acquire PiezoBioMembrane, which will become a wholly-owned subsidiary, expected to drive the development of medical devices and therapeutic products by integrating advanced functional biomaterials and piezoelectric technologies.
- Equity Structure Arrangement: Under the merger agreement, PBM shareholders will receive 3 million shares of PetVivo common stock, with a portion of the consideration tied to the achievement of key development and regulatory milestones, ensuring alignment with the company's strategic objectives for future value creation.
- Technology Platform Integration: This acquisition will provide PetVivo access to PBM's technology platform, including proprietary know-how, intellectual property, patents, and clinical information, which is anticipated to accelerate product development and commercialization efforts, enhancing the company's competitiveness in both animal and human health markets.
- Strategic Growth Potential: PetVivo CEO John Lai stated that this transaction represents a transformative step in the company's long-term growth strategy, and by combining PBM's innovative capabilities with PetVivo's market experience, it is expected to create significant value for patients and shareholders while supporting future research collaborations and innovation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
